肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

JCO：埃罗替尼、质子泵抑制剂同服，理想再来点可乐

2016-02-09 MedSci MedSci原创

埃罗替尼可乐质子泵抑制剂
关注

 埃罗替尼是一种口服酪氨酸激酶抑制剂，对于治疗非小细胞肺癌有着很好的效果。埃罗替尼口服的优势导致了一个新的相关的问题。埃罗替尼的胃肠道吸收是一个复杂的多因素导致的过程。其中影响吸收的最重要的一个因素就是胃内的pH。当埃罗替尼和质子泵抑制剂同服时，胃内pH值出现上升，直接导致了埃罗替尼生物利用度的下降。研究人员假设这两种药物的相互作用可以通过服用酸性可乐饮料逆转。 在这项随机、交

埃罗替尼是一种口服酪氨酸激酶抑制剂，对于治疗非小细胞肺癌有着很好的效果。埃罗替尼口服的优势导致了一个新的相关的问题。埃罗替尼的胃肠道吸收是一个复杂的多因素导致的过程。其中影响吸收的最重要的一个因素就是胃内的pH。当埃罗替尼和质子泵抑制剂同服时，胃内pH值出现上升，直接导致了埃罗替尼生物利用度的下降。研究人员假设这两种药物的相互作用可以通过服用酸性可乐饮料逆转。

在这项随机、交叉、药代动力学研究中，研究人员分析了病人间的吸收差异（血浆浓度时间曲线下面积，AUC）。研究人员在为期七天的埃罗替尼治疗、有或没有服用埃索美拉唑，引用可乐或者水。在第七天和第十四天的时候，病人住院一天进行药物代谢动力学样本取样。此项研究共包括了28名非小细胞肺癌患者。服用埃罗替尼和埃索美拉唑和可乐的患者中，平均的AUC增加了39%，而没有服用质子泵抑制剂的患者中，平均AUC仅在使用可乐服用埃罗替尼后稍微增高。

此项研究表明，在使用埃索美拉唑治疗的过程中，饮用可乐可以带来埃罗替尼生物利用度在临床相关和统计学上显著性增加。在没有接受质子泵抑制剂治疗的患者中，可乐的作用是很微小的。这些发现可以被用于优化临床治疗非小细胞肺癌的给药方案。

原始出处：
Roelof W.F et al. Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non–Small-Cell Lung Cancer. JCO. Published Ahead of Print on February 8, 2016 as 10.1200/JCO.2015.65.2560

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1667303, encodeId=594f166e303a7, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Wed Sep 28 07:39:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851291, encodeId=685018512918e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Oct 30 18:39:00 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891256, encodeId=a5ba189125622, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Mar 04 20:39:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569576, encodeId=6dc715695e65f, content=<a href='/topic/show?id=436d3841186' target=_blank style='color:#2F92EE;'>#可乐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38411, encryptionId=436d3841186, topicName=可乐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eede15532060, createdName=by2014, createdTime=Thu Feb 11 08:39:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582328, encodeId=39f61582328fa, content=<a href='/topic/show?id=020e415e867' target=_blank style='color:#2F92EE;'>#埃罗替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41578, encryptionId=020e415e867, topicName=埃罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dc016903257, createdName=luckyshitiancai_42705689, createdTime=Thu Feb 11 08:39:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63838, encodeId=4a49638384d, content=值得深究, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Feb 10 10:56:00 CST 2016, time=2016-02-10, status=1, ipAttribution=)]
    2016-09-28 shenxlcyp

    #质子泵#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1667303, encodeId=594f166e303a7, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Wed Sep 28 07:39:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851291, encodeId=685018512918e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Oct 30 18:39:00 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891256, encodeId=a5ba189125622, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Mar 04 20:39:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569576, encodeId=6dc715695e65f, content=<a href='/topic/show?id=436d3841186' target=_blank style='color:#2F92EE;'>#可乐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38411, encryptionId=436d3841186, topicName=可乐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eede15532060, createdName=by2014, createdTime=Thu Feb 11 08:39:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582328, encodeId=39f61582328fa, content=<a href='/topic/show?id=020e415e867' target=_blank style='color:#2F92EE;'>#埃罗替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41578, encryptionId=020e415e867, topicName=埃罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dc016903257, createdName=luckyshitiancai_42705689, createdTime=Thu Feb 11 08:39:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63838, encodeId=4a49638384d, content=值得深究, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Feb 10 10:56:00 CST 2016, time=2016-02-10, status=1, ipAttribution=)]
    2016-10-30 jklm09

    #抑制剂#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1667303, encodeId=594f166e303a7, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Wed Sep 28 07:39:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851291, encodeId=685018512918e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Oct 30 18:39:00 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891256, encodeId=a5ba189125622, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Mar 04 20:39:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569576, encodeId=6dc715695e65f, content=<a href='/topic/show?id=436d3841186' target=_blank style='color:#2F92EE;'>#可乐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38411, encryptionId=436d3841186, topicName=可乐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eede15532060, createdName=by2014, createdTime=Thu Feb 11 08:39:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582328, encodeId=39f61582328fa, content=<a href='/topic/show?id=020e415e867' target=_blank style='color:#2F92EE;'>#埃罗替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41578, encryptionId=020e415e867, topicName=埃罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dc016903257, createdName=luckyshitiancai_42705689, createdTime=Thu Feb 11 08:39:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63838, encodeId=4a49638384d, content=值得深究, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Feb 10 10:56:00 CST 2016, time=2016-02-10, status=1, ipAttribution=)]
    2016-03-04 lidong40

    #JCO#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1667303, encodeId=594f166e303a7, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Wed Sep 28 07:39:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851291, encodeId=685018512918e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Oct 30 18:39:00 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891256, encodeId=a5ba189125622, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Mar 04 20:39:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569576, encodeId=6dc715695e65f, content=<a href='/topic/show?id=436d3841186' target=_blank style='color:#2F92EE;'>#可乐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38411, encryptionId=436d3841186, topicName=可乐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eede15532060, createdName=by2014, createdTime=Thu Feb 11 08:39:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582328, encodeId=39f61582328fa, content=<a href='/topic/show?id=020e415e867' target=_blank style='color:#2F92EE;'>#埃罗替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41578, encryptionId=020e415e867, topicName=埃罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dc016903257, createdName=luckyshitiancai_42705689, createdTime=Thu Feb 11 08:39:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63838, encodeId=4a49638384d, content=值得深究, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Feb 10 10:56:00 CST 2016, time=2016-02-10, status=1, ipAttribution=)]
    2016-02-11 by2014

    #可乐#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1667303, encodeId=594f166e303a7, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Wed Sep 28 07:39:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851291, encodeId=685018512918e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Oct 30 18:39:00 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891256, encodeId=a5ba189125622, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Mar 04 20:39:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569576, encodeId=6dc715695e65f, content=<a href='/topic/show?id=436d3841186' target=_blank style='color:#2F92EE;'>#可乐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38411, encryptionId=436d3841186, topicName=可乐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eede15532060, createdName=by2014, createdTime=Thu Feb 11 08:39:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582328, encodeId=39f61582328fa, content=<a href='/topic/show?id=020e415e867' target=_blank style='color:#2F92EE;'>#埃罗替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41578, encryptionId=020e415e867, topicName=埃罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dc016903257, createdName=luckyshitiancai_42705689, createdTime=Thu Feb 11 08:39:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63838, encodeId=4a49638384d, content=值得深究, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Feb 10 10:56:00 CST 2016, time=2016-02-10, status=1, ipAttribution=)]
    2016-02-11 luckyshitiancai_42705689

    #埃罗替尼#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1667303, encodeId=594f166e303a7, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Wed Sep 28 07:39:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851291, encodeId=685018512918e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Oct 30 18:39:00 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891256, encodeId=a5ba189125622, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Mar 04 20:39:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569576, encodeId=6dc715695e65f, content=<a href='/topic/show?id=436d3841186' target=_blank style='color:#2F92EE;'>#可乐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38411, encryptionId=436d3841186, topicName=可乐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eede15532060, createdName=by2014, createdTime=Thu Feb 11 08:39:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582328, encodeId=39f61582328fa, content=<a href='/topic/show?id=020e415e867' target=_blank style='color:#2F92EE;'>#埃罗替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41578, encryptionId=020e415e867, topicName=埃罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dc016903257, createdName=luckyshitiancai_42705689, createdTime=Thu Feb 11 08:39:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63838, encodeId=4a49638384d, content=值得深究, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Feb 10 10:56:00 CST 2016, time=2016-02-10, status=1, ipAttribution=)]
    2016-02-10 dhzzm

    值得深究

    0

相关资讯

JCO：埃罗替尼不能延长NSCLC无病生存时间

 每年被诊断为肺癌的患者约有20-25%的可以切除治疗的非小细胞肺癌（NSCLC）。但是，仅有六成的患者可以在术后存活超过五年。在十年前第一次有报道基于顺铂的辅助化疗可以带来显著的存活率。随后其他的随机试验也证明了NSCLC2和3期患者接受辅助化疗可以存活更久。埃罗替尼是一种口服的小分子表皮生长因子受体酪氨酸激酶抑制剂，已经被证明对晚期肺癌有效。 研究人员首先假设埃罗替尼用于N

EJC：培美曲塞+埃罗替尼可改善非鳞状NSCLC生存

培美曲塞和埃罗替尼已被批准用于局部晚期或转移性非小细胞肺癌（NSCLC）患者二线治疗。美国礼来公司进行了一项多中心、随机、非盲、平行的II期临床试验，对培美曲塞单药及培美曲塞联合埃罗替尼用于非鳞状NSCLC患者治疗的疗效和安全性进行了评估，并于2014年4月将研究结果在线发表于《欧洲癌症杂志》（EJC）。患者入组标准为含有1处或1处以上经实体瘤疗效评价标准（RECIST）评估为可测量病灶，且美国东